Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms

Table 8 Diagnostic performance of biomarkers for stage IV lymphoma (n = 90)

Biomarker	AUC	95%CI	Sensitivity (%)	Specificity (%)	P value
SIRI	0.846	0.628-1.000	78.95	71.43	0.004a
PD-L1/CXCR3	0.872	0.771-0.973	84.21	71.43	0.002a
PD-1/CXCR3	0.959	0.903-1.000	89.47	85.71	< 0.001b
CXCR3/intermediate monocytes	0.720	0.508-0.932	78.95	71.43	0.067
SII	0.650	0.450-0.850	60.00	65.00	> 0.05
CXCR3/T-lymphocytes (%)	0.600	0.400-0.800	55.00	60.00	> 0.05
CXCR3/classical monocytes (%)	0.580	0.380-0.780	57.89	42.86	> 0.05
CXCR3/non-classical monocytes (%)	0.590	0.390-0.790	57.89	57.14	> 0.05

^aP < 0.01.

^bP < 0.001.

SIRI: Systemic inflammation response index; PD-L1: Programmed death-ligand 1; CXCR3: C-X-C motif chemokine receptor 3; PD-1: Programmed cell death protein 1; SII: Systemic immune-inflammation index; AUC: Area under the curve; CI: Confidence interval.